Key Takeaways Global point prevalence typically falls within ~0.5–2%, with heterogeneity by region and methodology. Childhood onset is common (≈30–50% […]
Key Takeaways Evidence for vitiligo has progressed from descriptive case series to randomized and phase-3 trials; the most mature clinical
Primary endpoint: Mean % change in F-VASI at week 24 better with NB-UVB vs PUVA (−48.6% vs −39.2%; Δ −9.4
Definition and Prevalence Vitiligo is a chronic skin disorder characterized by the development of depigmented (white) patches on the skin.